(VIANEWS) – Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) fell by a staggering 18.68% to kr2.29 at 11:37 EST on Friday, after five consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.07% to kr1,228.65, after two successive sessions in a row of gains. This seems, at the moment, a somewhat bullish trend exchanging session today.
NORDIC NANOVECTOR’s last close was kr2.81, 65.35% below its 52-week high of kr8.11.
About NORDIC NANOVECTOR
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin's lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases. The company is also developing 89Zr-NNV003, a CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors. The company has collaboration agreements with Orano Med; Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania development of a CD37-targeting CAR-T in haematological cancers. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-7.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -304.6%.
More news about NORDIC NANOVECTOR (NANOV.OL).
